News
-
-
PRESS RELEASE
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
DBV Technologies to participate in AAAAI/WAO Joint Congress to present long-term efficacy results of epicutaneous immunotherapy with VIASKIN peanut patch in peanut-allergic children aged 4-11 years, showcasing treatment benefits and high compliance rates -
-
-
-
-
-
-
-